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Autophagy is critical for the maintenance of organelle func-
tion and intracellular nutrient environment. Autophagy is also 
involved in systemic metabolic homeostasis, and its dysregula-
tion can lead to or accelerate the development of metabolic 
disorders. While the role of autophagy in the global metabo-
lism of model organisms has been investigated mostly using 
site-specific genetic knockout technology, the impact of 
dysregulated autophagy on systemic metabolism has been 
unclear. Here, we review recent papers showing the role of 
autophagy in systemic metabolism and in the development of 
metabolic disorders. Also included are data suggesting the 
role of autophagy in human-type diabetes, which are differ-
ent in several key aspects from murine models of diabetes. 
The results shown here support the view that autophagy 
modulation could be a new modality for the treatment of 
metabolic syndrome associated with lipid overload and hu-
man-type diabetes. 
 






Autophagy, literally meaning ‘self-eating,’ is a cellular process 
of degradation of the cell’s own internal material, such as 
proteins or organelles, in lysosomes. There are three major 
types of autophagy: macroautophagy, microautophagy, and 
chaperone-mediated autophagy. Among them, macroau- 
tophagy (hereafter referred to as autophagy) is a process 
involving the rearrangement of subcellular membranes, se-
questering the cytoplasm and organelles, which leads to the 
formation of an autophagosome surrounded by a double 
membrane. When autophagosomes fuse with lysosomes, 
autophagolysosomes are formed in which proteolysis of the 
sequestered material by lysosomal enzymes occurs (Klionsky 
and Emr, 2000). The main purpose of autophagy is quality 
control of organelles or proteins, and protection of the intra-
cellular nutrient environment. Thus, in the case of nutrient 
deficiency, intracellular macromolecules are degraded by 
autophagy to meet cellular requirements for energy and vital 
elements, suggesting that adaptive autophagy may have 
evolved from ancient cellular machinery supplying nutrients 
during energy crises in primordial unicellular organisms such 
as yeast. The autophagy machinery has been extensively 
characterized by many scientists, and the 2016 Nobel Prize 
for Physiology or Medicine was awarded to Yoshinori Ohsu-
mi as a tribute to his seminal discovery of the autophagy-
related (Atg) conjugation system. Outlining the detailed 
molecular and cellular mechanisms of autophagy is beyond 
the scope of this paper, and the readers are encouraged to 
consult excellent, previously published reviews (Klionsky, 
2016; Mizushima and Komatsu, 2011). 
Since autophagy is critical for the maintenance of cellular 
homeostasis and organelle function, it affects almost all 
physiological processes and, furthermore, is expected to 
influence the pathogenesis of a diverse range of diseases. 
Thus, dysregulated autophagy may lead to or be associated  
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with a variety of diseases, including metabolic disorders such 
as type 2 diabetes (T2D) or metabolic syndrome, neuro-
degenerative disorders such as Alzheimer’s disease, Parkin-
son’s disease or Huntington’s disease, immune/inflammatory 
disorders, infectious diseases, cancer and aging. Accordingly, 
autophagy modulation may have therapeutic potential on 
such disorders and conditions (Eisenberg et al., 2009; Ru-
binsztein et al., 2012; Shoji-Kawata et al., 2013; Zhang et al., 
2007). 
In this review, we summarize the recent progress made in 
understanding the role of systemic and local autophagy in 
the pathogenesis of metabolic disorders, and the prospect of 
using autophagy modulators as a new therapeutic option 
against diabetes and metabolic disorders. 
 
DIVERSE METABOLIC PHENOTYPES OF MICE 
WITH SITE-SPECIFIC AUTOPHAGY DISRUPTION 
 
Two main pathogenic axes in the development of T2D are 
insulin resistance and β-cell failure. Numerous theories have 
been proposed as mechanisms causing insulin resistance and 
β-cell failure such as lipid overload, reactive oxygen species, 
ER stress, mitochondrial dysfunction and low-grade meta-
bolic inflammation (Johnson and Olefsky, 2013). Besides 
such well-recognized factors, dysregulated autophagy and 
altered gut microbiota have recently been implicated as con-
tributing factors (Kim and Lee, 2014; Yang et al., 2017). 
While extensively studied, the role of autophagy in the 
maintenance of metabolic homeostasis and in the patho-
genesis of metabolic disorders has been controversial, which 
is partly due to the neonatal lethality of mice with systemic 
autophagy-knockout. Thus, the in vivo role of autophagy in 
metabolic disorders has been studied mostly using site-
specific gene knockout mouse models which have diverse 
metabolic features depending on the site and severity of 
autophagy knockout (Kim and Lee, 2014). For example, 
mice with knockout of Atg7, an essential autophagy gene in 
pancreatic β-cells producing insulin (Atg7Δb-cell mice), show 
structural and functional defects of pancreatic β-cells, result-
ing in glucose intolerance and susceptibility to diabetes in 
the presence of metabolic stress (Ebato et al., 2008; Jung et 
al., 2008; Quan et al., 2012a). While Atg7Δb-cell mice develop 
hyperglycemia but not diabetes, they do develop severe 
diabetes when crossed to ob/ob mice, suggesting that au-
tophagy is crucial in the metabolic adaptation of β-cells to 
metabolic stress (Quan et al., 2012a). On the other hand, 
autophagy knockout in skeletal muscle cells leads to the 
induction of fibroblast growth factor 21 (FGF21) as a ‘mito-
kine’ due to mitochondrial stress, and resistance to diet-
induced obesity or insulin resistance (Kim et al., 2013a), 
contrary to the expectation that autophagy deficiency asso-
ciated with mitochondrial dysfunction in insulin target tis-
sues would lead to insulin resistance. Autophagy knockout 
in the liver leads to the accumulation of lipid droplets due to 
impaired lipophagy (Singh et al., 2009a) or reduced hepatic 
lipid content after starvation or high-fat diet (HFD) feeding, 
due to enhanced lipid catabolism by fibroblast growth factor 
21 (FGF21) from autophagy-deficient hepatocytes (Kim et 
al., 2013b; Shibata et al., 2009), similar to the findings in 
skeletal muscle-specific autophagy knockout. In mice with 
white adipose tissue-specific autophagy knockout, reduced 
fat mass due to defective adipocyte differentiation was ob-
served, which was accompanied by the browning of white 
adipose tissue and resistance to diet-induced obesity or insu-
lin resistance (Singh et al., 2009b; Zhang et al., 2009). In 
contrast, mice with autophagy deletion in brown adipose 
tissue show defective brown adipose tissue differentiation 
but paradoxically increased body temperature due to in-
creased fatty acid oxidation in beige adipocytes (Martinez-
Lopez et al., 2013). Autophagy knockout in hypothalamic 
neurons has also been conducted, which led to obesity or 
leanness depending on the location of autophagy deletion 
(proopiomelanocortin vs. agouti-related protein neurons) 
(Coupe et al., 2012; Kaushik et al., 2011; 2012; Quan et al., 
2012b). 
 
METABOLIC CHANGES IN MICE WITH GLOBAL 
AUTOPHAGY INSUFFICIENCY 
 
Such diverse metabolic features of mice with autophagy 
knockout in various metabolic tissues raise a question – what 
is the effect of global autophagy insufficiency of a physiolog-
ical level on systemic metabolism and the development of 
metabolic disorders, since there is neither ‘tissue-specific’ 
autophagy nor ‘gene knockout’ in the real world. To answer 
this question, mice with systemic autophagy insufficiency of 
a physiologically relevant degree have been generated (Lim 
et al., 2014). Such Atg7+/- heterozygote or haploinsufficient 
mice showed no apparent abnormalities in their systemic 
metabolic profile in an unstressed or basal metabolic state. 
However, when Atg7+/- mice were crossed with leptin-
deficient ob/ob mice or fed a HFD, imposing metabolic stress, 
metabolic changes were observed. Atg7+/--ob/ob mice de-
veloped more severe and persistent diabetes compared to 
autophagy-competent ob/ob mice, which was accompanied 
by aggravated glucose intolerance and decreased insulin 
sensitivity. Histologically, more severe fat buildup in the liver 
and an increased number of crown-like structures (macro-
phages aggregating around dead adipocytes, indicating 
metabolic inflammation) in adipose tissue were noted, 
which was accompanied by an increased serum level of ala-
nine aminotransferase (ALT)/aspartate aminotransferase 
(AST), suggesting increased liver damage and a stronger 
induction of inflammatory cytokines in adipose tissue. The 
increased lipid accumulation in the livers of Atg7+/--ob/ob 
mice compared to autophagy-competent ob/ob mice might 
be related to compromised lipophagy. When the mechanism 
of increased metabolic inflammation was studied, enhanced 
inflammasome activation, characterized by increased caspa-
se-1 cleavage and pro-IL-1β maturation to IL-1β, was ob-
served in the stromal vascular fraction of adipose tissue from 
Atg7+/--ob/ob mice compared to that of autophagy-
competent ob/ob mice. Increased infiltration of macrophag-
es expressing IL-1β into the adipose tissue of Atg7+/--ob/ob 
mice was also observed by confocal microscopy (Fig. 1). The 
enhanced inflammasome activation in the adipose tissue of 
Atg7+/--ob/ob mice was probably due to aggravated mito-
chondr ial  dysfunct ion in metabol ical ly-stressed 
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Fig. 1. Infiltration of IL-1-producing macro-
phages into the adipose tissue of Atg7+/--ob/ob 
mice. Paraffin-embedded adipose tissue sec-
tions were stained with anti-IL-1β and anti-
F4/80 antibodies as the primary antibodies, 
and confocal microscopy was done (left). The 
number of IL-1β-producing macrophages in 
the adipose tissue of Atg7+/--ob/ob mice was 
higher than in the adipose tissue of Atg7+/+-




















macrophages, which play a crucial role in inflammasome 
activation by various NACHT, LRR and PYD domains-
containing protein 3 (NLRP3) activators (Misawa et al., 
2013; Vandanmagsar et al., 2011; Wen et al., 2011). Mito-
chondrial reactive oxygen species (ROS) production and the 
cellular fraction with lower mitochondrial potential observed 
after treatment with palmitic acid (PA) in combination with 
lipopolysaccharide (LPS) were increased in macrophages 
from autophagy-insufficient mice compared to those from 
autophagy-competent mice, probably due to less efficient 
removal or rejuvenation of stressed mitochondria in autoph-
agy-insufficient macrophages. The relationship between 
autophagic activity, mitochondrial stress, and inflammasome 
activation associated with lipid overload was more directly 
demonstrated in myeloid cell-specific Atg7-knockout mice 
(Lee et al., 2016). In these mice, metabolic deterioration, 
characterized by aggravated insulin resistance and elevated 
glucose levels, was observed after crossing them with ob/ob 
mice, similar to systemic Atg7-haploinsufficient mice. Atg7-
knockout macrophages showed increased mitochondrial 
stress and inflammasome activation after treatment with a 
combination of PA and LPS in vitro, as expected. Myeloid 
cell-specific deletion of Atg5, another critical autophagy 
gene, also led to the development of steatohepatitis associ-
ated with M1 polarization when the mice were fed a HFD 
and challenged with LPS (Liu et al., 2015), and aggravated 
atherosclerosis when they were crossed with LDL receptor-
knockout mice and fed a Western diet (Liao et al., 2012). 
Thus, increased inflammasome activation due to inefficient 
clearance of dysfunctional mitochondria acting as a hub for 
inflammasome activation (Misawa et al., 2013) and in-
creased lipid content probably due to compromised lipoph-
agy are the main culprits leading to the aggravated metabol-
ic deterioration seen in Atg7+/--ob/ob mice compared to 
autophagy-competent ob/ob mice. Furthermore, lipid ac-
cumulation can aggravate metabolic inflammation and in-
flammasome activation, since fatty acids can be activators of 
NLRP3 (Wen et al., 2011), linking the two events observed in 
Atg7+/--ob/ob mice (lipid accumulation and inflammasome 
activation). These results suggest that autophagy insufficien-
cy of a physiologically relevant degree might not cause sig-
nificant problems in managing basal metabolic stress, but 
can cause difficulty in dealing with increased metabolic stress, 
and autophagy insufficiency due to aging, genetics, or ex-
ogenous agents can be a factor in the development or ag-
gravation of metabolic syndrome or diabetes associated with 
lipid overload or obesity. This suggestion is consistent with 
previous papers demonstrating that overexpression of Atg5 
improves the metabolic profile of aged mice (Pyo et al., 
2013), and that mice that are defective in stimulus-induced 
autophagy show defective exercise-mediated protection 
against glucose intolerance after HFD feeding (He et al., 
2012). These data also suggest the possibility that systemi-
cally-enhanced autophagic activity by pharmacological 
agents may have beneficial effects on body-wide metabo-
lism during metabolic stress. Indeed, imatinib and trehalose 
have been shown to increase autophagic activity (Castillo et 
al., 2013; Dehay et al., 2010; Lin et al., 2015; Xie et al., 
2017), and were able to ameliorate the metabolic profile of 
ob/ob mice with systemic autophagy insufficiency, as 
demonstrated by increased autophagic activity and reduced 
inflammasome activation or cytokine expression in metabolic 
tissues (Lim et al., 2014). Natural products identified from a 
plant metabolite library have also been shown to improve 
metabolic profile by enhancing systemic autophagy (Fan et 
al., 2017). In line with these reports, spermidine that has 
been reported to enhance autophagy by modulating 
acetylproteome (Morselli et al., 2011), could improve cardiac 
function and extend the lifespan of aged mice (Eisenberg et 
al., 2016). These results imply that if bona fide autophagy 
enhancers without adverse effects could be developed, they 
could be candidates for novel therapeutic agents against 
diabetes, and metabolic syndrome associated with lipid over-
load or cardiovascular diseases. 
 
ROLF OR AUTOPHAGY IN HUMAN-TYPE DIABETES 
 
So far, we have discussed the role of autophagy in diabetes 
based on data generated using animal models. However, 
human diabetes and murine diabetes differ in several as-
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pects. One of the key differences is the accumulation of 
amyloids in islets that occurs in human diabetes but not in 
murine diabetes. Islet amyloid stained with Congo red is 
found in 90% of human subjects with diabetes (Kahn et al., 
1999). This striking dissimilarity is due to the differences in 
the amino acid sequence of islet amyloid polypeptide (IAPP) 
between mice and humans. Human IAPP (hIAPP) is amyloi-
dogenic, and murine IAPP (mIAPP) is nonamyloidogenic 
(Westermark et al., 2011), although it remains unclear why 
humans acquired IAPP amyloidogenicity during evolution. 
Amyloidogenic or aggregate-prone proteins are preferential-
ly cleared by autophagy, while nonamyloidogenic or soluble 
proteins can be cleared by both autophagy and proteasome 
pathways (Rubinsztein, 2006). Thus, the role of autophagy 
in human diabetes would be greater than in murine diabetes. 
To study the role of autophagy in human-type diabetes, 
transgenic mice expressing hIAPP in pancreatic β-cells driven 
by the rat insulin promoter (hIAPP+ mice) (Janson et al., 
1996; Verchere et al., 1996) were employed. hIAPP+ mice 
develop only mild hyperglycemia; however, when crossed 
with RIP-Cre; Atg7F/F mice to render them autophagy-
deficient in β-cells, hIAPP+Atg7Δb-cell mice developed diabetes 
(Kim et al., 2014; Rivera et al., 2014). These data suggest 
the importance of β-cell autophagy in protecting against 
hIAPP-induced diabetes. The role of hIAPP in the develop-
ment of diabetes was also investigated using hIAPP knock-in 
mice, which could be more physiologically relevant than the 
transgenic hIAPP overexpression model. In line with the re-
sults from hIAPP+Atg7Δb-cell mice, hIAPP knock-in:Atg7Δβ-cell 
mice showed more severe metabolic deterioration and fur-
ther reduction in β-cell mass compared to Atg7Δβ-cell mice 
when fed a HFD, while overt diabetes was not observed in 
those mice (Shigihara et al., 2014). 
When the mechanism of overt diabetes in hIAPP+Atg7Δb-cell 
mice was investigated, significant accumulation of hIAPP 
oligomers stained with an oligomer-specific antibody (A11 
or I11 antibody) and islet amyloids stained with Thioflavin S 
or (E,E)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styryl-
benzene (FSB) were observed by confocal microscopy in the 
pancreatic islets of hIAPP+Atg7Δb-cell mice (Kim et al., 2014) 
(Fig. 2). Accumulation of hIAPP oligomers can be an im-
portant event leading to overt diabetes in hIAPP+Atg7Δb-cell 
mice, since it is hypothesized that hIAPP oligomers, rather 
than hIAPP amyloids, may be a toxic effector molecule in-
ducing β-cell apoptosis according to the ‘toxic oligomer hy-
pothesis’ (Haataja et al., 2008). Indeed, increased apoptosis 
of pancreatic β-cells was observed in hIAPP+Atg7Δb-cell mice 
compared to hIAPP+Atg7F/F or hIAPP-Atg7Δb-cell mice. More-
over, when monkey islet cells expressing amyloidogenic IAPP 
in a manner similar to human islet cells were incubated with 
bafilomycin, blocking the lysosomal step of autophagy, ac-
cumulation of intracellular IAPP oligomers occurred with 
resultant apoptosis in vitro (Kim et al., 2014). The types of 
hIAPP oligomers accumulating when autophagy was blocked 
were also investigated. For this purpose, an HA tag was at-
tached to pro-hIAPP and pro-mIAPP. When INS-1 insulino-
ma cells were transfected with pro-mIAPP, only pro-mIAPP 
monomers were observed via immunoblot analysis using 













Fig. 2. Accumulation of hIAPP oligomers in hIAPP+ mice with β-
cell autophagy knockout (hIAPP+Atg7Δb-cell mice). Confocal mi-
croscopy after immunofluorescent staining of pancreas sections 
employing anti-insulin and anti-hIAPP oligomer (I11) antibodies. 
hIAPP oligomer accumulation was not seen when autophagy is 




pro-hIAPP dimers were observed in addition to pro-hIAPP 
monomers. When autophagy was blocked with 3-
methyladenine (3-MA), accumulation of pro-hIAPP dimers 
increased and a protein band consistent with pro-hIAPP 
trimers was also seen on immunoblot. Accumulation of pro-
hIAPP dimers or trimers was more pronounced in the deter-
gent-insoluble fraction compared to the detergent-soluble 
fraction, suggesting the possibility that pro-hIAPP dimers 
may be initially formed in membrane-rich compartments 
(e.g., secretory granule membranes) and translocate to the 
soluble fraction or proceed to form pro-hIAPP trimers in the 
membrane fraction. Accumulation of pro-hIAPP dimers or 
trimers disappeared when three amino acids critical for amy-
loid formation were changed to prolines, as seen in nonamy-
loidogenic pro-mIAPP. These results indicate that the amino 
acid sequence in this critical region determines the amyloi-
dogenicity of IAPP and suggest that pro-hIAPP dimers or 
trimers could be the initial seed proceeding to high-n hIAPP 
oligomers and hIAPP amyloids. These results are also con-
sistent with a report that pro-hIAPP aggregates are the dom-
inant form in the initial phase of islet amyloid formation, and 
may act as niduses for advanced intracellular amyloid and 
extracellular amyloid deposition in the later stages, together 
with mature IAPP (Paulsson et al., 2006). The biochemical 
reason for preferential pro-hIAPP dimer or trimer formation 
in the initial phase of islet amyloid formation could be the 
presence of a heparin binding domain in the N-terminal 
cleavage site and the higher isoelectric point of pro-hIAPP 
compared to mature hIAPP, which could enhance associa-
tion of hIAPP with negatively charged membranes (Jayasinghe 
and Langen, 2005; Park and Verchere, 2001; Paulsson et al., 
2006). Further studies will be required to elucidate the de-
tailed molecular and structural mechanisms governing the 
formation and progression of hIAPP amyloids. 
Since autophagy deficiency can lead to hIAPP oligomer 
formation, β-cell apoptosis and, finally, diabetes, the possibil-
ity that autophagy enhancement could improve β-cell func-
tion by accelerating clearance of hIAPP oligomers has been 
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Fig. 3. Proposed model for the development of diabetes 
with lipid overload or human-type diabetes with autoph-
agy insufficiency. Metabolic stress in the presence of 
autophagy insufficiency causes increased lipid accumu-
lation due to compromised lipophagy. Autophagy insuf-
ficiency leads to delayed clearance of dysfunctional 
mitochondria, which causes increased inflammasome 
activation when the cell is challenged with an inflam-
masome activator, such as lipids (green arrow). Au-
tophagy insufficiency also leads to accumulation of 
human IAPP (hIAPP) oligomers in pancreatic β-cells, 
since hIAPP clearance is dependent on autophagy. The 
combined effects of these three axes and their interac-
tions finally culminates in the development of insulin 



























tested. To this end, hIAPP+ mice were fed a HFD to make 
them diabetic. When trehalose was administered for four 
weeks to hIAPP+ mice given a HFD, their glucose profile 
significantly improved which was accompanied by reduced 
accumulation of hIAPP oligomers and islet amyloids, de-
creased β-cell apoptosis, and an enhanced insulinogenic 
index representing β-cell function (Kim et al., 2014). These 
results suggest that autophagy enhancers could be used as a 
novel therapeutic agent not only against murine diabetes 
with lipid overload, but also against human-type diabetes 
characterized by islet amyloid accumulation. 
While these results show that enhancement of β-cell au-
tophagy leads to improvement of β-cell function by clearing 
hIAPP oligomer, a recent paper suggested a different role of 
starvation-induced autophagy of pancreatic β-cells such as 
degradation of insulin granules inhibiting excessive release 
of insulin during fasting (Goginashvili et al., 2015). Thus, 
further studies will be required to unravel the functional 
complexity regarding the role of β-cell autophagy in the 




A number of mouse studies employing tissue-specific 
knockout of essential autophagy genes have revealed the 
important role and function of autophagy in controlling 
metabolic function. However, it has not been clear from 
those genetic studies how dysregulated autophagy could 
affect global or systemic metabolic features. Considering 
recent evidence that autophagy and mitophagy declines in 
aging (Sun et al., 2015), such a question could be a practical 
one related to the effect of aging and organelle dysfunction 
on body metabolism. Now, it is considered very likely that 
autophagy deficiency due to aging, genetic causes, or other 
factors could compromise an organism’s ability to adapt to 
metabolic stress, and predispose it to the development of 
metabolic syndrome and diabetes due to increased lipid 
accumulation and inflammasome activation when confront-
ed by metabolic or other types of stress (Fig. 3). Autophagy 
deficiency could be a predisposing factor for human-type 
diabetes in particular, since hIAPP oligomers or amyloids are 
preferentially cleared by autophagy (Fig. 3). Thus, it is highly 
likely that enhancement of autophagy could be a novel 
strategy against a global increase in the incidence of meta-
bolic syndrome and diabetes. 
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